– USA, NJ – Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat being vacated by the retirement of Dr. Jacques Gonella.
Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia, and currently serves as Chief Executive Officer for Eliminate Cancer, a cutting-edge oncology R&D and venture organization.
Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, “We are pleased to announce the addition of another seasoned pharmaceutical executive to the Antares Board of Directors. We believe Dr. Smith’s background in drug development and product registration will benefit our organization as we continue to expand the Company’s pipeline. We look forward to Karen’s contributions.”
about Dr Karen Smith
Dr. Smith has overseen more than 60 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including oncology, rare disease, cardiology, dermatology neuroscience and anti-infectives. In addition to R&D and pipeline development, Karen’s successful record of business development includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Prior to joining ECI, Karen served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc., and also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb. She is currently a member of the Board of Directors of Acceleron Pharma, ECI and Sangamo Therapeutics. Dr. Smith earned an MD from the University of Warwick, PhD in Molecular Oncology from UCLA (USA) and University of Western Australia, an MBA from the University of New England in Australia and LLM (Masters in Law) from the University of Salford.
Dr. Jacob continued, “The Board of Directors would like to thank Dr. Gonella for eighteen years of dedicated service, first as the founder of Antares Pharma and also as a significant contributor to the development of our Company. He served for eight years as our first Chairman of the Board of Directors. Dr. Gonella’s lengthy experience in R&D, operating and financial management as well as his knowledge concerning public companies has provided valuable insight regarding the Company’s operations. We wish him well in his retirement.”
About Antares Pharma
Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc. and Pfizer Inc. Antares Pharma’s proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
For more information : https://www.antarespharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.